Candidate molecule for premature ejaculation, DA-8031: In vivo and in vitro characterization of DA-8031

Urology

Volumn 77, Issue 4, 2011, Pages 1006.e17-1006.e21

  Jeon, Hyung Jun ^a   Kim, Hae Sun ^a   Lee, Chan Ho ^a   Lee, Young Gun ^a   Choi, Seol Min ^a   Sohn, Yong Sung ^a   Shin, Chang Yong ^a   Kim, Junghoon ^a   Shim, Hyun Joo ^a   Kang, Kyung Koo ^a   Ahn, Byoung Ok ^a   Kim, Soon Hoe ^a  

^a Dong A Pharmaceutical Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DA 8031; DOPAMINE; DOPAMINE TRANSPORTER; ISOBENZOFURAN DERIVATIVE; NORADRENALIN; NORADRENALIN TRANSPORTER; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BRAIN SYNAPTOSOME; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EJACULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREMATURE EJACULATION; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE; TREATMENT OUTCOME;

EID: 79953899827     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.11.046     Document Type: Article

References (21)

1. Waldinger MD. Emerging drugs for premature ejaculation. Expert Opin Emerg Drugs. 2006;11:99-109.
2. Hellstrom WJ. Current and future pharmacotherapies of premature ejaculation. J Sex Med. 2006;3(suppl 4):332-341. (Pubitemid 44269836)
3. Sadeghi-Nejad H, Watson R. Premature ejaculation: current medical treatment and new directions (CME). J Sex Med. 2008;5:1037-1050. (Pubitemid 351606695)
4. Gurkan L, Oommen M, Hellstrom WJ. Premature ejaculation: current and future treatments. Asian J Androl. 2008;10:102-109.
5. Atmaca M, Kuloglu M, Tezcan E, et al. The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002;14:502-505. (Pubitemid 36068429)
6. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 1994;151:1377-1379. (Pubitemid 24281766)
7. McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol. 1998;159:1935-1938. (Pubitemid 29190728)
8. Kara H, Avdin S, Yucel M, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol. 1996;156:1631-1632. (Pubitemid 26344007)
9. Giuliano F. 5-Hydroxytrypamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci. 2007;30:79-84. (Pubitemid 46164860)
10. Giuliano F, Clement P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol. 2006;50:454-466. (Pubitemid 44189074)
11. Ceglia I, Acconcia S, Fracasso C, et al. Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br J Pharmacol. 2004;142:469-478. (Pubitemid 38869860)
12. Hertel P, Didriksen M, Pouzet B, et al. Lu 35-138 ((+)-(S)-3-{1-[2-(1- acetyl-2,3-dihydro-1H-indol-3-yl) ethyl]-3,6-dihydro-2H-pyridine- 4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential. Eur J Pharmacol. 2007;573:148-160. (Pubitemid 47464217)
13. Taber MT, Wright RN, Molski TF, et al. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. Pharmacol Biochem Behav. 2005;80:521-528. (Pubitemid 40299354)
14. Aluisio L, Lord B, Barbier AJ, et al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. Eur J Pharmacol. 2008;587:141-146.
15. Yonezawa A, Watanabe C, Ando R, et al. Characterization of p-chloroamphetamine-induced penile erection and ejaculation in anesthetized rats. Life Sci. 2000;67:3031-3039.
16. Clément P, Peeters M, Bernabé J, et al. Brain oxytocin receptors mediate ejaculation elicited by 7-hydroxy-2-(di-N-propylamino) tetralin (7-OH-DPAT) in anaesthetized rats. Br J Pharmacol. 2008; 154:1150-1159. (Pubitemid 351915070)
17. Yonezawa A, Yoshizumi M, Ebiko M, et al. Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes. Pharmacol Biochem Behav. 2008;88:367-373. (Pubitemid 350266778)
18. Marson L, McKenna KE. The identification of a brainstem site controlling spinal sexual reflexes in male rats. Brain Res. 1990;515:303-308. (Pubitemid 20176130)
19. Yells DP, Prendergast MA, Hendricks SE, et al. Fluoxetine-induced inhibition of male rat copulatory behavior: modification by lesions of the nucleus paragigantocellularis. Pharmacol Biochem Behav. 1994;49:121-127. (Pubitemid 24297266)
20. Argiolas A, Melis MR, Vargiu L, et al. d(CH25Tyr(Me)-[Orn8]vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH-(1-24). Eur J Pharmacol. 1987;134:221-224. (Pubitemid 17015953)
21. Cantor JM, Binik YM, Pfaus JG. Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin. Psychopharmacology(Berl) Berl. 1999;144:355-362. (Pubitemid 29307260)